相关实验视频

Updated: Jun 27, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

在德国治疗类风湿性关节炎的菲尔戈提尼布的现实世界经验:回顾性图表审查

Olaf Schultz¹, Christoph Fiehn², Christian Kneitz³

¹ACURA Kliniken Baden-Baden/Rheumazentrum, Rotenbachtalstraße 5, 76530, Baden-Baden, Germany. O.Schultz@acura-kliniken.com.

Zeitschrift fur Rheumatologie

|April 30, 2024

概括

在德国的类风湿性关节炎患者中,菲尔戈提尼布的实际使用显示出有效性和良好的耐受性,主要是作为单一疗法. 需要进一步的长期研究来证实这些发现在大型人群中.

科学领域:

类风湿病学类风湿病学
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

关于菲尔戈提尼布 (filgotinib) 的现实世界数据是有限的,它是一种Janus激酶 (JAK) 1抑制剂,用于类风湿性关节炎 (RA).
了解filgotinib在RA治疗中的实际应用至关重要.

研究的目的:

调查德国RA患者中的菲尔戈提尼布的实际使用模式.
收集有关患者特征,治疗方法和与菲尔戈提尼布治疗相关的结果的见解.

主要方法:

来自20个德国风湿病学中心的301名RA患者的回顾性图表审查.
分析包括患者人口统计学,先前的治疗,菲尔戈提尼布开始/停止治疗的原因,疾病活性 (CDAI),剂量调整和并发药物.
数据收集覆盖了至少6个月的预启动或诊断后的数据收集,并对filgotinib使用进行了随访.

主要成果:

大多数患者 (83.7%) 开始使用菲尔戈替尼作为单一疗法,通常是200毫克剂量.
启动的常见原因包括口服,快速起作用和单一治疗.
6个月后,36.8%的患者实现了临床疾病活动指数 (CDAI) 缓解,45.6%的患者达到低疾病活动. 18.4%的患者在12个月后停止治疗,主要是由于缺乏有效性.

结论:

菲尔戈提尼布在德国的临床实践中用于RA,这是由于剂量灵活性和JAK抑制剂的好处.
该药物表现出有效性和一般耐受性,主要是作为单一疗法.
建议对更大的队列进行进一步的前性研究,以评估长期结果.

关键词:

临床试验中的临床试验.亚努斯酶1抑制剂的使用追溯研究是回顾性研究.类风湿性类风湿性类风湿性治疗的合理性治疗的理由

更多相关视频

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...